Results 161 to 170 of about 3,267 (182)
HPLC method development, validation and impurity characterization for an antitumor Hsp90 inhibitor—PU-H71 (NSC 750424) [PDF]
Journal of Pharmaceutical and Biomedical Analysis, 2014 An HPLC method for the assay of the heat shock protein 90 inhibitor, PU-H71 (NSC 750424), has been developed and validated. The stress testing of PU-H71 was carried out in accordance with ICH guidelines Q1A (R2) under aqueous, acidic, alkaline, oxidative, thermolytic and photolytic conditions.
Mingtao, Liu +6 more
exaly +3 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
2023
The Minor Planet Electronic Circulars contain information on unusual minor planets, routine data on comets and natural satellites, and occasional editorial announcements. They are published on behalf of Division F of the International Astronomical Union by the Minor Planet Center, Smithsonian Astrophysical Observatory, Cambridge, MA 02138, U.S.A.
openaire +1 more source
The Minor Planet Electronic Circulars contain information on unusual minor planets, routine data on comets and natural satellites, and occasional editorial announcements. They are published on behalf of Division F of the International Astronomical Union by the Minor Planet Center, Smithsonian Astrophysical Observatory, Cambridge, MA 02138, U.S.A.
openaire +1 more source
Naunyn-Schmiedeberg's Archives of Pharmacology, 2019
Heat shock protein 90 (HSP90) inhibitors are considered as new radiosensitizing agents. PU-H71, a novel HSP90 inhibitor, is under evaluation for the treatment of advanced cancer. It is however not known whether PU-H71 alters radiosensitivity of metastatic breast cancer.
Nuray Erin
exaly +3 more sources
Heat shock protein 90 (HSP90) inhibitors are considered as new radiosensitizing agents. PU-H71, a novel HSP90 inhibitor, is under evaluation for the treatment of advanced cancer. It is however not known whether PU-H71 alters radiosensitivity of metastatic breast cancer.
Nuray Erin
exaly +3 more sources
Mechanism of the antimyeloma activity of PU-H71, a novel purine scaffold HSP90 inhibitor.
Journal of Clinical Oncology, 20108141 Background: PU-H71, a novel purine scaffold HSP90 inhibitor, has demonstrated anti-tumor activity in triple-negative breast cancer and Bcl6 dependent B-cell lymphoma preclinical models.
S. Z. Usmani +3 more
openaire +1 more source
Activity of PU-H71, a novel HSP90 inhibitor, and bortezomib in Ewing sarcoma preclinical models.
Journal of Clinical Oncology, 20133101 Background: Heat shock protein (HSP) 90 regulates the disposition and activity of a large number of deregulated proteins in Ewing sarcoma. We have shown pre-clinical efficacy of PU-H71, a novel HSP90 inhibitor developed at MSKCC, in Ewing sarcoma. Unfolded proteins as a result of HSP90 inhibition are degraded via the ubiquitin-proteasome pathway
Srikanth R. Ambati +8 more
openaire +1 more source
Cancer Research, 2019
Abstract Background: The epichaperome is a new cancer target required for tumor survival (Joshi et al. Nature Reviews Cancer 2018). PU-H71 is a synthetic, purine scaffold epichaperome inhibitor that binds to the ATP-binding site of HSP90 specifically when HSP90 is integrated into the epichaperome (Rodina et al. Nature 2016).
K Jhaveri +16 more
openaire +1 more source
Abstract Background: The epichaperome is a new cancer target required for tumor survival (Joshi et al. Nature Reviews Cancer 2018). PU-H71 is a synthetic, purine scaffold epichaperome inhibitor that binds to the ATP-binding site of HSP90 specifically when HSP90 is integrated into the epichaperome (Rodina et al. Nature 2016).
K Jhaveri +16 more
openaire +1 more source
Abstract 7326: PU-H71 alters metabolism to suppress growth in pancreatic cancer
Cancer ResearchAbstract Pancreatic ductal adenocarcinoma (PDAC) is a deadly cancer with limited therapeutic options. Oncogenic KRAS signaling, mainly via the mitogen-activated protein kinase (MAPK) pathway, is the key driver of PDAC. To sustain its growth and resist therapy, PDAC tumors continuously reprogram their metabolic activities.
Chiamaka J. Ezeh +3 more
openaire +1 more source
Antitumor Efficacy of the Purine-Scaffold Hsp90 Inhibitor PU-H71 in Diffuse Large-B Cell Lymphoma
Blood, 2008Abstract Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma. Although many DLBCLs are responsive to CD20 antibody/chemotherapy regimens, a significant proportion of patients will still die of their disease. It is possible that targeting important lymphomagenic pathways could improve the potency and reduce the ...
Gabriela Chiosis +4 more
openaire +1 more source
Foodservice Research International, 1999
Ground beef was inoculated with E. coli O157:H7 and treated with gamma radiation with and without the incorporation of a 2% soluble polylactic acid solution (SPLA) and stored at 4C for up to 7 days. Frozen samples received an average maximum dose of 125 krads, at an average dose rate of 17.1 krads/h.
TOM WILSON +4 more
openaire +1 more source
Ground beef was inoculated with E. coli O157:H7 and treated with gamma radiation with and without the incorporation of a 2% soluble polylactic acid solution (SPLA) and stored at 4C for up to 7 days. Frozen samples received an average maximum dose of 125 krads, at an average dose rate of 17.1 krads/h.
TOM WILSON +4 more
openaire +1 more source
A facile and efficient synthesis of d6‐labeled PU‐H71, a purine‐scaffold Hsp90 inhibitor
Journal of Labelled Compounds and Radiopharmaceuticals, 2009AbstractPU‐H71 is a purine‐scaffold Hsp90 inhibitor currently undergoing late stage preclinical evaluation for the treatment of cancer. In this investigation, we present a simple method for the synthesis of d6‐labeled PU‐H71 for use as an internal standard to accurately quantitate the drug in biological matrices based on an LC‐MS‐MS method.
Tony Taldone +3 more
openaire +1 more source